Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867541 | 0.87 | KMT2A (0.48) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL23551355 | 0.85 | GPR84 (0.56) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL21366096 | 0.83 | NR4A2 (0.65) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL21366224 | 0.80 | MEN1 (0.68) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL21366110 | 0.79 | MAPT (0.72) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL21366231 | 0.79 | MEN1 (0.67) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL30100928 | 0.78 | MAPT (0.52) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL22462594 | 0.78 | NR4A2 (0.65) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL22644138 | 0.77 | MAPT (0.61) | MEN1KMT2AMAPTNR4A2CREBBP | |
| SCHEMBL29567209 | 0.77 | MEN1 (1.00) | MEN1KMT2AMAPTNR4A2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| WO-2021127302-A1 | 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210179604-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200354353-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885MAPT 4673/4885 |
| US-20210179604-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MEN1 2883/4885KMT2A 1124/4885MAPT 2556/4885 |
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | MEN1 2883/4885KMT2A 1124/4885MAPT 2556/4885 |
| US-20200354353-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MEN1 2883/4885KMT2A 1124/4885MAPT 2556/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | MEN1 1911/4885KMT2A 1118/4885MAPT 3515/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MEN1 2883/4885KMT2A 1124/4885MAPT 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.